# Orforglipron ATTAIN-1: oral weight loss results at 72 weeks

Source: https://pepvault.app/research/orforglipron-attain-1-2025

Last updated: 2026-11-17

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Research](https://pepvault.app/research) [Orforglipron](https://pepvault.app/research#orforglipron)

Randomized trial · people

# Orforglipron 36 mg: 11.2% weight loss at 72 weeks in ATTAIN-1

Checked against the paper November 2026 Randomized trial [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The takeaway

In a large 72-week trial, daily oral orforglipron led to more weight loss than placebo at every dose tested, with gut side effects as the most common problem.

- **Kind:** Randomized trial
- **Studied in:** People
- **Number studied:** 3127
- **Published:** 2025
- **Journal:** N Engl J Med

## What they tested

The team tested whether once-daily orforglipron, taken by mouth, lowers body weight more than placebo in adults with obesity who do not have diabetes.

## How the study was done

A phase 3, multinational, randomized, double-blind, placebo-controlled trial in 3127 adults with obesity and no diabetes, who took orforglipron at 6 mg, 12 mg or 36 mg, or placebo (a dummy treatment), once a day for 72 weeks. Everyone also followed a healthy diet and physical activity.

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking orforglipron? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What they found

At 72 weeks, average body weight changed by -7.5% in the 6 mg arm, -8.4% in the 12 mg arm and -11.2% in the 36 mg arm, compared with -2.1% on placebo, and each dose beat placebo. In the 36 mg arm, 54.6% lost at least 10% of their weight, 36.0% lost at least 15% and 18.4% lost at least 20%, compared with 12.9%, 5.9% and 2.8% on placebo. Waist size, systolic blood pressure (the top number), triglycerides and non-HDL cholesterol also improved more than on placebo. Side effects led 5.3 to 10.3% of people on orforglipron to stop treatment, versus 2.7% on placebo, and the most common were gut-related effects that were mostly mild to moderate.

## What it doesn’t show

The trial included only adults with obesity who did not have diabetes, and it compared orforglipron with placebo, not with other weight-loss medicines. It was funded by Eli Lilly.

## The paper

Wharton et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025.

- [PubMed (PMID 40960239)](https://pubmed.ncbi.nlm.nih.gov/40960239/)
- [The paper (DOI 10.1056/NEJMoa2511774)](https://doi.org/10.1056/NEJMoa2511774)
- [ClinicalTrials.gov (NCT05869903)](https://clinicaltrials.gov/study/NCT05869903)

## The compound

- [Orforglipron: how it works, half-life, studied range and evidence](https://pepvault.app/peptides/orforglipron)
- [Orforglipron dose guide](https://pepvault.app/lab/dosage/orforglipron)

## With this study

### Orforglipron

- [Orforglipron: the full reference](https://pepvault.app/peptides/orforglipron)
- [Orforglipron dose guide](https://pepvault.app/lab/dosage/orforglipron)

### Studies

- [Orforglipron: heart events no worse than insulin in ACHIEVE-4](https://pepvault.app/research/orforglipron-achieve-4-2026)
- [Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2](https://pepvault.app/research/orforglipron-attain-2-2026)
- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026)
- [All 5 studies](https://pepvault.app/research#orforglipron)

### Compared with

- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)
- [Orforglipron vs Semaglutide (oral)](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide-oral)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)

### Tools

- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)

## More studies on Orforglipron

- [Orforglipron: heart events no worse than insulin in ACHIEVE-4](https://pepvault.app/research/orforglipron-achieve-4-2026) Randomized trial · people · 2026
- [Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2](https://pepvault.app/research/orforglipron-attain-2-2026) Randomized trial · people · 2026
- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026) Randomized trial · people · 2026
- [Orforglipron: food lowered drug exposure by 17.6% to 23.7%](https://pepvault.app/research/orforglipron-ma-2024) Clinical trial · people · 2024
- [Every study on Orforglipron](https://pepvault.app/research#orforglipron)

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed November 2026. Spot an error? [feedback@pepvault.app](mailto:feedback@pepvault.app). [How we research](https://pepvault.app/guides/how-we-research). This page reports one study; it is not medical advice.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking orforglipron? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking orforglipron? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this study

### Orforglipron

- [Orforglipron: the full reference](https://pepvault.app/peptides/orforglipron)
- [Orforglipron dose guide](https://pepvault.app/lab/dosage/orforglipron)

### Studies

- [Orforglipron: heart events no worse than insulin in ACHIEVE-4](https://pepvault.app/research/orforglipron-achieve-4-2026)
- [Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2](https://pepvault.app/research/orforglipron-attain-2-2026)
- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026)
- [All 5 studies](https://pepvault.app/research#orforglipron)

### Compared with

- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)
- [Orforglipron vs Semaglutide (oral)](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide-oral)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)

### Tools

- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)

<!--promo-->

PepVault for iPhone

## Taking orforglipron? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Research

- [All studies](https://pepvault.app/research)
- [Every study on Orforglipron](https://pepvault.app/research#orforglipron)

## The library

- [Orforglipron](https://pepvault.app/peptides/orforglipron)
- [Orforglipron dose guide](https://pepvault.app/lab/dosage/orforglipron)
- [The peptide reference library](https://pepvault.app/peptides)

## How we work

- [How we research](https://pepvault.app/guides/how-we-research)
- [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
